Ascites from patients with encapsulating peritoneal sclerosis augments NIH/3T3 fibroblast proliferation.
Encapsulating peritoneal sclerosis (EPS) remains one of the major causes of dropout in continuous ambulatory peritoneal dialysis by reducing ultrafiltration capacity. To demonstrate whether ascites from patients with EPS (EPS ascites) has fibroblast proliferation activity, we used NIH/3T3 fibroblasts to examine the effects of EPS ascites on fibroblast proliferation activity by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Encapsulating peritoneal sclerosis ascites dose-dependently augmented NIH/3T3 fibroblast proliferation. The protein kinase C inhibitors and the tyrosine kinase inhibitors partially inhibited the stimulatory effects of EPS ascites on fibroblast proliferation activity. In EPS ascites, levels of interleukin (IL)-1beta, IL-6, IL-8, transforming growth factor (TGF)-beta1, hepatocyte growth factor (HGF), and platelet-derived growth factor (PDGF)-AB were elevated. The treatment with IL-1beta, HGF, TGF-beta1, and PDGF-AB alone or in combination at similar concentrations to those in EPS ascites exhibited small but significant fibroblast proliferation activities. We conclude that EPS ascites stimulate NIH/3T3 fibroblast proliferation via protein kinase C and tyrosine kinase. The elevated cytokine and growth factors partly contribute to the EPS ascites-induced fibroblast proliferation.
Masunaga
Yoshinori
Y
Department of Nephrology, Jichi Medical School, Minamikawachi, Kawachi, Tochigi, Japan.
Muto
Shigeaki
S
Asakura
Shinji
S
Akimoto
Tetsu
T
Homma
Sumiko
S
Kusano
Eiji
E
Asano
Yasushi
Y
D000818:Animals; D001201:Ascites / Q000209:etiology / Q000473:pathology*; D002455:Cell Division; D016207:Cytokines / Q000302:isolation & purification / Q000502:physiology; D005260:Female; D005347:Fibroblasts / Q000473:pathology*; D006133:Growth Substances / Q000302:isolation & purification / Q000502:physiology; D006801:Humans; D008297:Male; D051379:Mice; D008875:Middle Aged; D041681:NIH 3T3 Cells; D010529:Peritoneal Cavity / Q000473:pathology*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D011493:Protein Kinase C / Q000378:metabolism; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D012598:Sclerosis / Q000209:etiology / Q000473:pathology
D016207:Cytokines; D006133:Growth Substances; D011505:Protein-Tyrosine Kinases; D011493:Protein Kinase C